Farnesylthiosalicylic Acid Through Inhibition of Galectin-3 Improves Neuroinflammation in Alzheimer Disease via Multiple Pathways.
Autor: | Qiu Q; Department of Pharmacology, School of Pharmacy, Nantong University, Nantong, Jiangsu, China., Li C; Department of Pharmacology, School of Pharmacy, Nantong University, Nantong, Jiangsu, China., Zhao X; Department of Pharmacology, School of Pharmacy, Nantong University, Nantong, Jiangsu, China., Yang M; Department of Pharmacology, School of Pharmacy, Nantong University, Nantong, Jiangsu, China., Ding S; Department of Pharmacology, School of Pharmacy, Nantong University, Nantong, Jiangsu, China., Liang H; Department of Pharmacy, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China., Chen T; Department of Pharmacology, School of Pharmacy, Nantong University, Nantong, Jiangsu, China. |
---|---|
Jazyk: | angličtina |
Zdroj: | CNS neuroscience & therapeutics [CNS Neurosci Ther] 2024 Nov; Vol. 30 (11), pp. e70127. |
DOI: | 10.1111/cns.70127 |
Abstrakt: | Aims: Many factors affect the neuroinflammatory response in patients with Alzheimer disease (AD). Galectin-3 (Gal-3) is closely related to microglial activation in the nervous system and can promote the aggregation of cancer cells in tumors. This study aimed to investigate the mechanism by which farnesylthiosalicylic acid (FTS) affects neuroinflammation in Aβ Methods: We used the Morris water maze, reverse transcription-polymerase chain reaction (RT-PCR), Western blotting, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence to conduct our study. Results: FTS reduced the levels of proinflammatory factors and microglial activation in Aβ Conclusion: FTS may through inhibiting Gal-3 reduce the expression of TLR4 and CD14 and alleviate Aβ pathology, downregulating Aβ-stimulated TLR2, TLR4, and CD14 expression, and thus alleviate neuroinflammation in Aβ (© 2024 The Author(s). CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.) |
Databáze: | MEDLINE |
Externí odkaz: |